Sutent (Pancreatic Cancer) - Analysis and Forecasts to 2020

Sutent (Pancreatic Cancer) - Analysis and Forecasts to 2020

Summary

GlobalData’s pharmaceuticals report, “Sutent (Pancreatic Cancer) - Analysis and Forecasts to 2020” provides Sutent sales forecasts for the US, and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2010-2020). The report also includes information on Pancreatic Cancer market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

Scope

- Therapy area profile including patient population for the US and EU5
- Analysis and review of Sutent including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Sutent including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecasts for 2010-2020 for Sutent in the US and EU5

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Introduction 4
2.1 Pancreatic Cancer 4
2.2 Pancreatic Cancer Market 4
2.3 Epidemiology 4
2.4 Etiology 6
2.4.1 Cigarette Smoking 6
2.4.2 Age 6
2.4.3 Gender 7
2.4.4 Family History 8
2.4.5 Other Factors 8
2.5 GlobalData Market Forecasts Report Guidance 9
3 Pancreatic Cancer: Market Characterization 10
3.1 Pancreatic Cancer Market 10
3.2 Pancreatic Cancer Market Forecasts and CAGR 10
3.3 Drivers for Pancreatic Cancer Market 11
3.3.1 High Prevalence 11
3.3.2 High Incidence 11
3.3.3 Large Unmet Need 12
4 Tumor-Node-Metastases(TNM) Classification of Pancreatic Cancer 13
5 Sutent 16
5.1 Introduction 16
5.2 Mechanism of Action 16
5.3 Clinical Studies 16
5.4 Approval History of Sutent 17
5.5 Factors Affecting Sales of Sutent 17
5.5.1 Pancreatic Cancer Market 17
5.5.2 Niche market 17
5.5.3 Superior Efficacy 17
5.5.4 Emergence of Targeted Therapies 17
5.5.5 Approval in Japan 17
5.6 Drug Evaluation 18
5.6.1 Drug Risk Benefit Score 18
5.6.2 Intensity of Competition 18
5.7 Sales Forecasts 19
5.7.1 Target Patient Pool of Sutent 19
5.7.2 Dosing 19
5.7.3 Market Penetration 19
5.7.4 Annual Cost of Therapy 20
5.7.5 Sales Projections of Sutent 20
6 Pancreatic Cancer Market: Appendix 28
6.1 Market Definitions 28
6.2 Abberiviations 28
6.3 Research Methodology 28
6.3.1 Coverage 28
6.3.2 Secondary Research 29
6.3.3 Forecasting 29
6.3.4 Number of Patients Approved to take the Drug 29
6.3.5 Net Penetration of Drug 29
6.3.6 Net Annual Dosing 30
6.3.7 Annual Cost of Therapy 31
6.3.8 Primary Research 31
6.3.9 Expert Panels 31
6.4 Contact Us 31
6.5 Disclaimer 31
6.6 Sources 32